Ralfinamide mesylate

Cat. No.:	HY-101437A
CAS No.:	202825-45-4
Molecular Formula:	$C_{18}H_{23}FN_2O_5S$
Molecular Weight:	398.45
Target:	Sodium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	Ralfinamide mesylate (FCE-26742A mesylate) is an orally available **Na^+ channel** blocker derived from α-aminoamide, with function of suppressing pain[1][2].
IC_{50} & Target	Na^+channel[1]
In Vivo	Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain[1].

Animal Model:	81 adult male Sprague–Dawley male rats (260–460 g)[1]
Dosage:	80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative)
Administration:	Oral gavage; twice daily; until postoperative day 42
Result:	Suppressed neuropathic pain.

REFERENCES

[1]. Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305.

[2]. Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA